Financial Performance - The company's operating revenue for Q1 2022 was ¥12,468,040.78, representing a decrease of 58.50% compared to the same period last year[5] - The net profit attributable to shareholders was -¥2,641,751.10, and the net profit after deducting non-recurring gains and losses was -¥6,850,483.65, both classified as not applicable[5] - The net cash flow from operating activities decreased by 83.66%, amounting to ¥6,134,019.46[5] - Total operating revenue for Q1 2022 was CNY 12,468,040.78, a decrease of 58.5% compared to CNY 30,044,808.74 in Q1 2021[20] - Total operating costs for Q1 2022 were CNY 21,145,299.52, down 43.7% from CNY 37,645,517.67 in Q1 2021[20] - Net loss for Q1 2022 was CNY 2,641,751.10, an improvement from a net loss of CNY 5,294,732.69 in Q1 2021[21] - The company reported a gross profit margin of approximately -70.5% in Q1 2022, compared to -20.7% in Q1 2021[20] - The company’s total liabilities as of Q1 2022 were CNY 276,603,531.94, a decrease from CNY 293,119,657.58 in Q1 2021[20] - The total equity attributable to shareholders was CNY 1,458,728,409.59 in Q1 2022, slightly down from CNY 1,461,370,160.69 in Q1 2021[20] - Basic and diluted earnings per share for Q1 2022 were both CNY -0.03, an improvement from CNY -0.09 in Q1 2021[21] Cash Flow and Investments - The net cash flow from investing activities was 63,593,297.03, compared to a negative cash flow of -89,929,121.58 in the previous period[25] - The total cash outflow from investing activities amounted to 71,261,786.05, while the previous period recorded 90,110,091.60[25] - Cash inflow from financing activities was 10,000,000.00, down from 76,760,000.00 in the previous period[25] - The net cash flow from financing activities was 9,844,444.45, significantly lower than 73,465,202.36 in the previous period[25] - The net increase in cash and cash equivalents was 79,571,760.94, compared to 21,073,452.90 in the previous period[25] - The ending balance of cash and cash equivalents reached 116,257,683.14, up from 109,087,225.38 in the previous period[25] - The company paid 155,555.55 in dividends and interest, a decrease from 3,294,797.64 in the previous period[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,735,331,941.53, a decrease of 1.09% from the end of the previous year[6] - The company reported a total current asset of RMB 987,446,356.87, down from RMB 1,069,701,592.05 at the end of 2021[16] - The total non-current assets increased to RMB 747,885,584.66 from RMB 684,788,226.22 year-over-year[17] - Cash and cash equivalents amounted to RMB 116,257,683.14, significantly up from RMB 36,685,922.20[16] - The company’s accounts receivable decreased to RMB 279,300,504.19 from RMB 342,755,037.35[16] - The company’s inventory increased to RMB 54,779,472.06 from RMB 27,977,602.20[16] - Short-term borrowings rose to RMB 20,021,388.88 from RMB 10,010,694.44[17] - The company’s total assets were RMB 1,735,331,941.53, slightly down from RMB 1,754,489,818.27[17] Research and Development - Research and development expenses totaled ¥5,623,502.12, accounting for 45.10% of operating revenue, an increase of 16.37 percentage points year-on-year[6] - The company is actively engaged in research and development, with ongoing projects progressing normally[14] - Research and development expenses for Q1 2022 were CNY 2,949,671.40, down 49.3% from CNY 5,815,948.24 in Q1 2021[20] Market and Sales - The decline in operating revenue was attributed to a decrease in sales volume of the quadrivalent influenza vaccine due to the impact of the COVID-19 pandemic[10] - The company highlighted the seasonal nature of its flu vaccine sales, with peak sales occurring from September to December[14] Financial Management - The company experienced a significant increase in cash and cash equivalents, with a rise of 216.90% due to the maturity and redemption of financial products[9] - The company’s financial expenses decreased by 109.59%, mainly due to a reduction in borrowing and interest expenses[10] - The company did not apply the new accounting standards starting from 2022[25]

Financial Performance - The company's operating revenue for 2021 was ¥392,272,487.50, a decrease of 33.41% compared to ¥589,098,682.33 in 2020[22]. - The net profit attributable to shareholders for 2021 was ¥82,460,219.55, down 46.79% from ¥154,979,429.69 in 2020[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥65,828,539.56, a decline of 59.34% from ¥161,884,159.12 in 2020[22]. - The net cash flow from operating activities was ¥103,925,232.98, a decrease of 5.05% compared to ¥109,455,543.90 in 2020[22]. - The total assets at the end of 2021 were ¥1,754,489,818.27, an increase of 125.52% from ¥777,975,861.13 at the end of 2020[22]. - The net assets attributable to shareholders increased to ¥1,461,370,160.69, a significant rise of 502.62% from ¥242,504,379.14 at the end of 2020[22]. - The basic earnings per share for 2021 were ¥1.10, down 53.19% from ¥2.35 in 2020[23]. - The gross profit margin for the main business was 85.56%, a decrease of 1.93 percentage points compared to the previous year[87]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 12.16%, up 7.32 percentage points from 4.84% in 2020[23]. - R&D expenditures (including capitalization) reached CNY 47.71 million, an increase of CNY 19.18 million or 67.21% year-on-year[36]. - The company completed the Phase III clinical trial for the lyophilized human rabies vaccine and is progressing with the Phase I trial for the quadrivalent influenza vaccine for children[36]. - The company has developed four core platform technologies for vaccine production, including chicken embryo-based vaccine preparation technology and cell-based virus culture technology, which support a wide range of vaccine types[60]. - The company is developing a quadrivalent influenza vaccine series, including a pediatric version for children under 3 years and a high-dose version for seniors over 65[73]. - The company has a rich pipeline of 9 major products in development targeting 5 infectious diseases, which will help maintain strong market competitiveness[73]. Market and Industry Insights - The global vaccine market size was $30.5 billion in 2018, accounting for 3.5% of the global pharmaceutical market, and is projected to reach $44.8 billion by 2024, with a CAGR of 6.6%[49]. - China's vaccine market revenue was approximately ¥33.17 billion in 2018, expected to grow to ¥101.77 billion by 2023, reflecting a CAGR of 25.1%[50]. - The flu vaccine coverage rate in China is only 4.2%, compared to over 40% in Europe and the U.S., suggesting a large domestic market opportunity[52]. - The domestic influenza vaccine coverage rate is currently low, with significant growth potential as the market shifts from trivalent to quadrivalent vaccines[40]. - The increasing awareness of vaccine benefits and government support for innovation are expected to drive growth in the Chinese vaccine market, narrowing the gap with developed countries[54]. Corporate Governance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[8]. - The company has not violated decision-making procedures for external guarantees[8]. - The company has not disclosed any significant changes in shareholder structure or share movements[9]. - The company has established a structured governance framework involving the shareholders' meeting, board of directors, independent directors, supervisory board, and senior management to ensure effective internal control[184]. - The company has implemented an employee stock incentive plan, which has been fully granted to core technical personnel and other key individuals, with the first grant completed during the reporting period[188]. Environmental and Social Responsibility - The company emphasizes ESG (Environmental, Social, and Governance) practices, integrating them into its corporate culture to promote sustainable development[187]. - The company has constructed and operates a wastewater treatment station to ensure compliance with discharge standards[191]. - The company has established an emergency response plan for environmental incidents, which has been filed with environmental authorities[193]. - The company has successfully passed environmental impact assessments for its construction projects[192]. - The company has implemented a self-monitoring plan for environmental compliance, with no exceedances reported during the monitoring period[194]. Future Outlook and Strategy - The company is committed to becoming a leading Chinese biotechnology company in the human vaccine field with international standards[137]. - Future outlook indicates a strong focus on new product development and technological advancements, aiming to enhance market competitiveness[149]. - The company plans to accelerate the clinical research of its pipeline products that have received clinical approval[138]. - The company intends to expand its sales team and enhance marketing efforts to increase brand awareness and market competitiveness[138]. - The company is exploring market expansion strategies, particularly in the biopharmaceutical sector, to capture a larger market share[149].

Financial Performance - The company's operating revenue for Q3 2021 reached ¥316,767,790.30, representing an increase of 81.06% compared to the same period last year[5] - Net profit attributable to shareholders was ¥123,380,194.62, a year-on-year increase of 123.40%[5] - The net profit excluding non-recurring gains and losses was ¥120,485,663.84, up 120.16% from the previous year[5] - Basic and diluted earnings per share were both ¥1.53, reflecting an increase of 82.14% compared to the same period last year[6] - Total operating revenue for the first three quarters of 2021 reached ¥348,862,016.53, an increase from ¥262,359,887.82 in the same period of 2020, representing a growth of approximately 33%[24] - Net profit for the first three quarters of 2021 was ¥100,075,142.54, up from ¥48,419,117.67 in 2020, reflecting a growth of approximately 106.7%[25] - Basic and diluted earnings per share for the third quarter of 2021 were both ¥1.41, compared to ¥0.73 in the same quarter of 2020, marking an increase of 92.5%[25] Assets and Liabilities - Total assets increased by 123.47% to ¥1,738,571,446.61 compared to the end of the previous year[6] - Total assets as of the end of the third quarter of 2021 amounted to ¥1,738,571,446.61, significantly higher than ¥777,975,861.13 at the end of the same period in 2020[22] - Total liabilities for the third quarter of 2021 were ¥259,586,362.93, down from ¥535,471,481.99 in 2020, indicating a reduction of approximately 51.5%[21] - The company's total equity reached ¥1,478,985,083.68 by the end of the third quarter of 2021, compared to ¥242,504,379.14 in the same period of 2020, showing a substantial increase of about 509%[22] Cash Flow - The company reported a cash flow from operating activities of ¥25,239,042.68, a decrease of 25.63% compared to the previous year[6] - Operating cash inflow for the first three quarters of 2021 was CNY 339,639,556.36, a significant increase from CNY 168,733,413.73 in the same period of 2020, representing a growth of 101.0%[27] - Net cash flow from operating activities decreased to CNY 25,239,042.68 in 2021 from CNY 33,935,881.85 in 2020, a decline of 25.6%[27] - Total cash outflow from investment activities was CNY 848,163,575.38, compared to CNY 43,392,098.16 in the previous year, indicating a substantial increase in investment spending[28] - Net cash flow from financing activities rose to CNY 829,125,729.89 in 2021, up from CNY 16,638,747.35 in 2020, reflecting a significant increase in financing efforts[28] Research and Development - The company's R&D investment totaled ¥9,703,935.67, which is 3.06% of operating revenue, a decrease of 1.60 percentage points year-on-year[6] - Research and development expenses for the first three quarters of 2021 were ¥28,861,387.14, compared to ¥22,041,130.46 in 2020, reflecting an increase of approximately 31%[24] Shareholder and Stock Information - The company plans to grant 800,000 restricted stocks under the 2021 incentive plan, representing 0.91% of the total share capital[17] - The first grant of 652,000 restricted stocks was approved, accounting for 0.74% of the total share capital[18] - The company’s employee stock incentive plan involves 369 participants, representing 93.42% of the total employees[17] - The company’s major shareholders include China Industrial Bank and China Construction Bank, with significant holdings in various investment funds[15] Investment and Market Strategy - The increase in revenue was primarily driven by steady growth in the sales of quadrivalent influenza vaccines[10] - The company emphasized its focus on technological innovation and quality management, which contributed to improved gross margins and reduced sales expenses[10] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[24]

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2021, representing a 25% increase compared to the same period last year[1]. - The company's operating revenue for the first half of 2021 was ¥32,094,226.23, a decrease of 63.28% compared to ¥87,408,320.39 in the same period last year[21]. - The net profit attributable to shareholders was -¥23,305,052.08, significantly lower than -¥6,808,867.72 in the previous year[21]. - The basic earnings per share for the first half of 2021 was -¥0.35, down from -¥0.13 in the same period last year[22]. - The company achieved a revenue of 32.09 million yuan and a net profit attributable to shareholders of -23.31 million yuan for the first half of 2021[60]. - The company reported a total profit for the first half of 2021 was a loss of ¥27,181,937.88, compared to a loss of ¥4,102,207.33 in the same period of 2020[170]. - The company reported a significant increase in credit impairment losses of ¥11,417,526.91 in the first half of 2021, compared to a reversal of -¥1,038,999.04 in the first half of 2020[170]. - The comprehensive income for the period shows a decrease of 23,305,052.08, indicating a significant loss[198]. Research and Development - Research and development expenses accounted for 87.53% of operating revenue, an increase of 71.66 percentage points compared to 15.87% in the previous year[22]. - The company has focused on expanding its vaccine product pipeline, which includes vaccines for influenza, rabies, chickenpox, shingles, and pneumonia[29]. - The company has developed a pipeline of 9 research products covering 5 major infectious diseases, including quadrivalent influenza vaccines for children currently in Phase I clinical trials[33]. - The company is advancing multiple vaccine projects, including a projected total investment of ¥10 million for the lyophilized human rabies vaccine, which has already incurred cumulative costs of ¥8.09 million[51]. - The total R&D investment reached approximately ¥28.09 million, a 102.55% increase compared to the previous period, with R&D expenses accounting for 87.53% of operating revenue[47]. - The company has established cell banks for vaccine development and production using MRC-5, Vero, and CHO cell lines, enhancing its capabilities in large-scale cell culture and bioreactor technology[39]. - The company is actively upgrading traditional vaccines and innovating new vaccines to expand its product pipeline in line with industry trends[33]. Market Expansion and Strategy - The company is planning to expand its market presence in Southeast Asia, targeting a 30% market share by the end of 2022[1]. - The company has completed a strategic acquisition of a biotech firm for RMB 200 million, enhancing its R&D capabilities[1]. - The company is exploring partnerships with international health organizations to enhance its global distribution network[1]. - The company aims to become a leading player in the human vaccine sector with international standards[29]. - The company has established a marketing network covering over 1,300 disease control centers across 28 provinces in China, laying a solid foundation for future brand development and market expansion[34]. Financial Position and Assets - The company's total assets at the end of the reporting period were ¥780,579,822.22, a slight increase of 0.33% from ¥777,975,861.13 at the end of the previous year[21]. - Cash and cash equivalents increased by 21.36% to CNY 106,809,600.52 compared to the previous year[1]. - Accounts receivable decreased by 61.31% to CNY 137,337,194.71, attributed to improved management and collection of receivables[1]. - Inventory rose by 92.63% to CNY 64,051,931.23, mainly due to an increase in work-in-progress at the end of the period[2]. - The company’s asset-liability ratio stood at 71.82%[66]. - The total liabilities reported were ¥560,651,063.16, compared to ¥535,471,481.99 previously, indicating a rise of about 4.3%[168]. Risks and Challenges - The company has identified potential risks related to supply chain disruptions, which may impact production timelines[1]. - The company is facing risks related to the commercialization of new products, with uncertainties in clinical trials and market competition[64]. - Seasonal fluctuations in demand for the four-valent influenza vaccine are expected, with peak sales typically occurring from September to December[65]. - The decline in revenue was attributed to the seasonal nature of influenza vaccine sales and increased R&D expenses[23]. Shareholder Commitments and Governance - The company has committed to a 36-month lock-up period for shares held by major shareholders, during which they cannot transfer or propose buybacks of their shares[93]. - The company has established commitments to ensure continuous and stable operations, including clear disclosure of control arrangements post-IPO[95]. - The controlling shareholder commits to stabilizing the company's stock price according to the established plan, with specific conditions and responsibilities outlined[111]. - The company will comply with the regulations regarding the reduction of shares held by shareholders, requiring at least three trading days' notice before any reduction if they hold more than 5% of shares[109]. - The company guarantees that the contents of the prospectus do not contain false records or misleading statements, and will bear legal responsibility for any inaccuracies[130]. Product Development and Innovation - New product development includes the launch of a novel vaccine, with an expected production capacity of 10 million doses per month starting Q3 2021[1]. - The quadrivalent influenza vaccine is the first of its kind in China to apply for clinical trials and achieve market sales, showcasing the company's innovation in vaccine development[35]. - The company has developed a new polysaccharide purification process that eliminates the use of phenol, significantly improving the quality of polysaccharide vaccines[41]. - The company is enhancing its pre-filled syringe production capacity to meet the growing demand for various vaccine formulations[42].